New appointment at Merck & Co
This article was originally published in Scrip
Merck & Co has named Dr Michael Mendelsohn senior vice-president of Merck Research Laboratories and franchise head, atherosclerosis and cardiovascular research. He joins the company after 17 years at Tufts Medical Center in Boston. He was the founder and for twelve years the executive director of the Center's Molecular Cardiology Research Institute, and for the past two years served as the first chief scientific officer at Tufts. Dr Mendelsohn will be based at Merck's site in Rahway, New Jersey, and will report to the company's senior vice-president, global scientific strategy, Dr Luciano Rossetti.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.